EGF–ERBB signalling: towards the systems level
Ami Citri, Yosef Yarden · Nature Reviews Molecular Cell Biology · 2006
Cited by 2,004 works. doi:10.1038/nrm1962
Authors
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Untangling the ErbB signalling network
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
- DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
- Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing